Sputnik Light vaccine (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% efficacy among the elderly in Argentina

Sputnik Light vaccine (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% efficacy among the elderly in Argentina

Moscow, June 2, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that the Russian Sputnik Light coronavirus vaccine (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% efficacy among the elderly according to real world data collected by the Ministry of Health of the Buenos Aires province (Argentina).

According to the data from over 186,000 people aged 60-79, more than 40,000 of whom received a shot of Sputnik Light (first dose of Sputnik V) as part of the mass-scale civil vaccination program, the infection rate between 21st and 40th day from the date of receiving the first dose was only 0.446%.

At the same time, the infection rate among non-vaccinated adult population was 2.74% for a comparable period.

The following formula was used to calculate the vaccine's efficacy:

Adjusted data weighted by age, gender and a number of other parameters among groups of vaccinated and non-vaccinated subjects demonstrated comparable efficacy of the Russian vaccine - 78.6%.

Positive official data of vaccination with single-dose Sputnik Light confirms the great efficacy of the vaccine and its potential for being used during the vaccination campaign in Argentina.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:

“The publication of independent data in Buenos Aires province confirms high efficacy of the Russian vaccine for senior citizens who are in a high-risk group. An efficacy level of near 83.7% is higher than that of many two-dose vaccines. As the report of the Ministry of Health of the province has demonstrated, vaccination with Sputnik Light (the first component of the Sputnik V vaccine) can significantly reduce the number of infections and hospitalizations. We plan to continue cooperating with colleagues in Argentina for further data on the use of the Russian vaccine.”

Sputnik V and Sputnik Light have a number of key advantages:

·        Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;

·        Efficacy of Sputnik Light is 79.4% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with the single dose vaccine from December 5, 2020 to April 15, 2021;

·        Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V;

·        The Sputnik V and Sputnik Light vaccines are based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.

·        Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.

·        The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

·        There are no strong allergies caused by Sputnik V.

·        The storage temperature of Sputnik V and Sputnik Light at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.

·        The price of Sputnik V and Sputnik Light is less than $10 per shot, making it affordable around the world.

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru

For additional information contact:

Alexey Urazov                                             Andrew Leach / Maria Shiryaevskaya

Russian Direct Investment Fund                Hudson Sandler

Director for External Communications

Mobile: +7 915 312 76 65                            Tel: +44 (0) 20 7796 4133

E-mail: Alexey.Urazov@rdif.ru